Document Detail

Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine (betaGBP).
MedLine Citation:
PMID:  14555235     Owner:  NLM     Status:  MEDLINE    
Cancer therapies based on drugs designed to interfere with specific targets within the molecular circuitry of cancer cells are currently under intense experimentation. Our strategy is based on the use of a naturally occurring immunomolecule which can selectively kill cancer cells, based on its ability to exploit genetic differences between normal and cancer cells. The betaGBP cytokine has previously been shown to negatively regulate the cell cycle by blocking cells in late S phase. In tumour cells, but not in normal cells, the S phase block has been shown to be followed by apoptosis. Mechanisms involved in S phase arrest have been pinpointed to downregulation of signalling and altered expression of cell cycle controller proteins, including E2F1, a transcription factor with ability to play a part in apoptosis. Here we discuss the use of betaGBP within the context of cancer surveillance and cancer therapeutics focussing on E2F1 as one mechanistic aspect relevant to betaGBP's selective induction of programmed cell death in cancer.
Livio Mallucci; Valerie Wells; Antonios Danikas; Derek Davies
Related Documents :
24022305 - The cell block method increases the diagnostic yield in exudative pleural effusions acc...
23545945 - Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer...
20924795 - Induction of the mitochondria apoptosis pathway by phytohemagglutinin erythroagglutinat...
21155915 - Cancer prevention and health promotion for people with intellectual disabilities: an ex...
22729835 - Runx3 downregulation in human lung adenocarcinoma is independent of p53, egfr or kras s...
24330465 - Total mesorectal excision with water-jet dissection in patients with rectal cancer: sur...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Biochemical pharmacology     Volume:  66     ISSN:  0006-2952     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-13     Completed Date:  2003-11-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1563-9     Citation Subset:  IM    
School of Health and Life Sciences, Cell Signalling and Growth Laboratory, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NN, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Breast Neoplasms / pathology
Cell Cycle Proteins*
Cell Division / drug effects
Cytokines / pharmacology*
DNA-Binding Proteins*
E2F Transcription Factors
E2F1 Transcription Factor
Galectins / pharmacology*
Genes, cdc / physiology*
Lymphoma, B-Cell / pathology
Transcription Factors / physiology
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cell Cycle Proteins; 0/Cytokines; 0/DNA-Binding Proteins; 0/E2F Transcription Factors; 0/E2F1 Transcription Factor; 0/E2F1 protein, human; 0/Galectins; 0/Transcription Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  p73 and p63 protein stability: the way to regulate function?
Next Document:  Apoptosis in male germ cells in response to cyclin A1-deficiency and cell cycle arrest.